Comparison · NCT03318783-sae
GSK2256294 vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. GSK2256294 vs Placebo: serious adverse events. Trial comparisons, record NCT03318783-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03318783-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.4 | 0.168 | 0.687 | wilson | |
| Risk in group 2 | 0.556 | 0.267 | 0.811 | wilson | |
| Risk difference, group 1 minus group 2 | -0.156 | -0.501 | 0.252 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.72 | 0.276 | 1.88 | log | |
| Odds ratio, group 1 over group 2 | 0.533 | 0.086 | 3.31 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on GSK2256294 than on Placebo | 6.43 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | GSK2256294 | 10mg capsules of GSK2256294 will be administered in a single dose once daily enterally for a duration of 10 days.~GSK2256294: GSK2256294 will be administered in a single dose once daily enteral for a duration of 10 days. | 4 | 10 | EG000 |
| Group 2 | Placebo | 10mg matched placebo capsules will be administered in a single dose once daily enterally for a duration of 10 days.~Placebo: Placebo will be administered in a single dose once daily enteral for a duration of 10 days. | 5 | 9 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Adverse event data was collected up to 90 days after hospital discharge at the time of followup phone visit
Source ClinicalTrials.gov
Trial
- Title
- Subarachnoid Hemorrhage and Soluble Epoxide Hydrolase Inhibition Trial
- NCT number
- NCT03318783
- Phases
- PHASE1, PHASE2
- Conditions
- Subarachnoid Hemorrhage, Aneurysmal, Delayed Cerebral Ischemia, Vasospasm, Cerebral, Endothelial Dysfunction
- Interventions
- GSK2256294, Placebo
- Lead sponsor
- Oregon Health and Science University
- Results first posted
- 2021-01-22
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03318783?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03318783-sae